Trinity Biotech PLC revenue by segment TRIB

Annual Quarterly

Trinity Biotech PLC splits its revenue into 3 lines in its filings. The largest line in fiscal 2024, which ended Dec 31, 2024 was Clinical Laboratory at $39.4 million, 64% of the total.

USD in millions. The percent under a figure is the change from the year before.

FY 2024
Dec 31, 2024
FY 2023
Dec 31, 2023
FY 2022
Dec 31, 2022
FY 2021
Dec 31, 2021
FY 2020
Dec 31, 2020
FY 2019
Dec 31, 2019
FY 2018
Dec 31, 2018
FY 2017
Dec 31, 2017
Revenue
62
57
63
81
102
90
97
99
Clinical Laboratory
39
-6.9%
share 64.0%
42
-8.1%
share 74.4%
46
-26.8%
share 73.6%
63
-25.4%
share 77.5%
84
+23.7%
share 82.6%
68
share 75.3%
—
—
Point Of Care
17
+91.8%
share 28.3%
9
-1.3%
share 16.0%
9
-10.9%
share 14.7%
10
+12.2%
share 12.7%
9
-19.1%
share 9.0%
11
share 12.6%
—
—
Laboratory Services
5
-12.9%
share 7.7%
5
-25.0%
share 9.6%
7
-8.3%
share 11.6%
8
-6.6%
share 9.8%
8
-22.3%
share 8.3%
11
share 12.1%
—
—
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. More on our methodology.

Company profile

Industry
In Vitro & In Vivo Diagnostic Substances (SIC 2835)
Listed as
TRIB (Nasdaq)
Fiscal year ends
December 31
Incorporated in
Ireland
Headquarters
Wicklow
SEC filer status
Non-accelerated filer
SEC CIK
888721

Other In Vitro & In Vivo Diagnostic Substances companies

All 21 In Vitro & In Vivo Diagnostic Substances companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.